NEVRO CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-12-01: Form 8-K; Period of report 2023-11-30; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; Details 1.01.
- 2023-11-01: Form 8-K; Period of report 2023-11-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2023-08-01: Form 8-K; Period of report 2023-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2023-07-07: Form 8-K; Period of report 2023-06-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-12-01 | 8-K | 2023-11-30 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure | 1.01 On November 30, 2023, Nevro Corp. (“Nevro” or the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) pursuant to which it acquired all of the issued and outstanding shares of Interventional Pain Technologies, Inc. d/b/a Vyrsa Technologies (“Vyrsa”), a corporation organized under the laws of the Commonwealth of Pennsylvania that develops medical devices (the “Vyrsa Acquisition”). 2.01 The disclosure set forth under Item 1.01 is incorporated by reference herein. 2.03 The disclosure set forth in Item 1.01 above is incorporated by reference into this Item 2.03. 3.02 The disclosure set forth under Item 1.01 is incorporated herein by reference. 7.01 On November 30, 2023, the Company issued a press release announcing the transactions described herein, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference. | d941369d8k.htm |
| 2023-11-01 | 8-K | 2023-11-01 | 2.02 Results of Operations and Financial Condition | 2.02 On November 1, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and nine months ended September 30, 2023. | nvro-20231101.htm |
| 2023-08-01 | 8-K | 2023-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and six months ended June 30, 2023. | nvro-20230801.htm |
| 2023-07-07 | 8-K | 2023-06-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with the departure of Niamh Pellegrini from Nevro Corp. (the “Company”), effective as of June 9, 2023 (the “Separation Date”) that was previously announced on June 5, 2023, Ms. Pellegrini entered into a separation agreement (the “Separation Agreement”) with the Company dated as of June 30, 2023. | nvro-20230630.htm |
| 2023-06-05 | 8-K | 2023-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 5, 2023, Nevro Corp. (the “Company”) announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of the Company, effective June 19, 2023. | nvro-20230605.htm |
| 2023-05-30 | 8-K | 2023-05-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As previously announced in the Current Report on Form 8-K filed on April 19, 2023 by Nevro Corp. (the “Company”), Kevin Thornal, the current Chief Executive Officer and President of the Company, was appointed to the Company’s board of directors (the “Board”) on May 25, 2023, immediately following the conclusion of the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”). 5.07 At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 12, 2023 (the “Proxy”). | nvro-20230525.htm |
| 2023-04-26 | 8-K | 2023-04-26 | 2.02 Results of Operations and Financial Condition | 2.02 On April 26, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months ended March 31, 2023. | nvro-20230426.htm |
| 2023-04-19 | 8-K | 2023-04-19 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On April 19, 2023, Nevro Corp (“Nevro” or the “Company”) issued a press release that included its preliminary unaudited revenue for the first quarter of 2023 and that reaffirmed the Company’s 2023 full year guidance. 5.02 On January 9, 2023, the Company announced that D. Keith Grossman intends to retire as Chief Executive Officer and President following the selection of his successor. | nvro-20230419.htm |
| 2023-02-16 | 8-K | 2023-02-16 | 2.02 Results of Operations and Financial Condition | 2.02 On February 16, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months and full year ended December 31, 2022. | nvro-20230216.htm |
| 2023-01-09 | 8-K | 2023-01-09 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On January 9, 2023, Nevro Corp. (“Nevro” or the “Company”) issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022. 5.02 On January 9, 2023, the Company announced that Mr. D. Keith Grossman has informed the Board of Directors of the Company of his intention to retire as the Company’s Chief Executive Officer and President in 2023 following the selection of his successor. | nvro-20230109.htm |